Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Houyanqing Oral Liquid is a traditional Chinese medicine (TCM) herbal preparation developed for the prevention and treatment of radiation-induced oral mucositis (RIOM), particularly in patients with nasopharyngeal carcinoma undergoing radical radiotherapy. The formulation is composed of four primary medicinal herbs: *Achyranthes aspera* L., *Kalimeris indica* (L.) Sch.-Bip., *Plantago asiatica* L., and *Carpesium abrotanoides* L. It is intended to leverage the combined anti-inflammatory, analgesic, and tissue-repair properties of these botanical constituents to reduce the severity of mucosal damage caused by ionizing radiation. The drug is typically administered as an oral solution alongside conventional oral hygiene and symptomatic support measures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Houyanqing Oral Liquid.